A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer-Reference-Cited by-同舟云学术

A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer

Published:2008-05 Issue:5 Volume:19 Page:909-914
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Glimelius B.,Sørbye H.,Balteskard L.,Byström P.,Pfeiffer P.,Tveit K.,Heikkilä R.,Keldsen N.,Albertsson M.,Starkhammar H.,Garmo H.,Berglund Å.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/19/5/909/400785/mdm588.pdf

Reference31 articles.

1. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group;Saltz;N Engl J Med,2000

2. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial;Douillard;Lancet,2000

3. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer;de Gramont;J Clin Oncol,2000

4. Another study of how to give fluorouracil?;Saltz;J Clin Oncol,2003

5. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel;Rothenberg;J Clin Oncol,2001

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study);Acta Oncologica;2024-05-02

2. A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer;ESMO Open;2022-10

3. A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials;American Journal of Clinical Oncology;2022-07-15

4. Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer;Multidisciplinary Treatment of Colorectal Cancer;2020-11-17

5. Magnitude of advantage in tumor response contributes to a better correlation between treatment effects on overall survival and progression-free survival: a literature-based meta-analysis of clinical trials in patients with metastatic colorectal cancer;International Journal of Clinical Oncology;2020-01-16